Krisztina Takacs-Novak

Prof. Dr. Krisztina Takacs-Novak

Department of Pharmaceutical Chemistry, Semmelweis University, H-1092 Hőgyes Endre u. 9. Budapest, Hungary

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
KTKrisztina Takacs-Novak
Krisztina Takacs-Novak
VSVera Szőke
Vera Szőke
GVGergely Völgyi
Gergely Völgyi
HPHorváth Péter
Horváth Péter
RARita Ambrus
Rita Ambrus
PSPiroska Szabó-Révész
Piroska Szabó-Révész

13 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DCDóra Csicsák
Dóra Csicsák
RSRita Szolláth
Rita Szolláth
SKSzabina Kádár
Szabina Kádár
Rita AmbrusRita Ambrus
Rita Ambrus
CBCsilla Balla-Bartos
Csilla Balla-Bartos
GVGergely Völgyi
Gergely Völgyi
Particle size reduction is a commonly used process to improve the solubility and the dissolution of drug formulations. The solubility of a drug in the gastrointestinal tract is a crucial parameter, because it can greatly influence the bioavailability. This work provides a comprehensive investigation of the effect of the particle size, pH, biorelevant media and polymers (PVA and PVPK-25) on the solubility and dissolution of drug formulations using three model compounds with different acid-base characteristics (papaverine hydrochloride, furosemide and niflumic acid). It was demonstrated that micronization does not change the equilibrium solubility of a drug, but it results in a faster dissolution. In contrast, nanonization can improve the equilibrium solubility of a drug, but the selection of the appropriate excipient used for nanonization is essential, because out of the two used polymers, only the PVPK-25 had an increasing effect on the solubility. This phenomenon can be explained by the molecular structure of the excipients. Based on laser diffraction measurements, PVPK-25 could also inhibit the aggregation of the particles more effectively than PVA, but none of the polymers could hold the nanonized samples in the submicron range until the end of the measurements.

1 August 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GVGábor Vizserálek
Gábor Vizserálek
SBSzilvia Berkó
Szilvia Berkó
GTGergő Tóth
Gergő Tóth
RBRéka Balogh
Réka Balogh
MBMária Budai-Szűcs
Mária Budai-Szűcs
KTKrisztina Takacs-Novak
Krisztina Takacs-Novak

1 December 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
THTamás Horváth
Tamás Horváth
RARita Ambrus
Rita Ambrus
GVGergely Völgyi
Gergely Völgyi
MBMária Budai-Szűcs
Mária Budai-Szűcs
ÁMÁrpád Márki
Árpád Márki
PSPiroska Szabó-Révész
Piroska Szabó-Révész

1 August 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KTKrisztina Takacs-Novak
Krisztina Takacs-Novak
MUMaria Urac
Maria Urac
HPHorváth Péter
Horváth Péter
GVGergely Völgyi
Gergely Völgyi
BABradley D. Anderson
Bradley D. Anderson
AAAlex Avdeef
Alex Avdeef

29 June 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
EBEnikő Borbás
Enikő Borbás
PTPetra Tőzsér
Petra Tőzsér
KTKonstantin Tsinman
Konstantin Tsinman
OTOksana Tsinman
Oksana Tsinman
KTKrisztina Takacs-Novak
Krisztina Takacs-Novak
ZNZsombor Kristóf Nagy
Zsombor Kristóf Nagy